EP0701563A4 - Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote - Google Patents

Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Info

Publication number
EP0701563A4
EP0701563A4 EP94910861A EP94910861A EP0701563A4 EP 0701563 A4 EP0701563 A4 EP 0701563A4 EP 94910861 A EP94910861 A EP 94910861A EP 94910861 A EP94910861 A EP 94910861A EP 0701563 A4 EP0701563 A4 EP 0701563A4
Authority
EP
European Patent Office
Prior art keywords
mammalian host
connective tissue
product
gene encoding
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94910861A
Other languages
German (de)
English (en)
Other versions
EP0701563A1 (fr
Inventor
Joseph C Glorioso
Christopher H Evans
Paul D Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP0701563A1 publication Critical patent/EP0701563A1/fr
Publication of EP0701563A4 publication Critical patent/EP0701563A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte à un procédé permettant d'introduire au moins un gène codant un produit dans au moins une cellule d'un tissu conjonctif d'un mammifère hôte afin de traiter ce dernier. Ce procédé consiste à utiliser des techniques de recombinaison pour produire une molécule vecteur d'ADN contenant le gène codant pour le produit, et à infecter la cellule conjonctive du mammifère hôte au moyen de la molécule vecteur d'ADN comprenant le gène codant pour le produit. L'invention se rapporte également à un procédé permettant d'introduire au moins une cellule d'un tissu conjonctif d'un mammifère hôte par une voie non virale. Un procédé de production d'un modèle animal destiné à l'étude de la pathologie des tissus conjonctifs est également décrit, ainsi qu'un procédé d'utilisation in vivo d'un gène codant un domaine de liaison d'interleukine-1 extracellulaire d'un récepteur d'interleukine-1.
EP94910861A 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote Withdrawn EP0701563A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2775093A 1993-03-08 1993-03-08
US27750 1993-03-08
PCT/US1994/002414 WO1994020517A1 (fr) 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Publications (2)

Publication Number Publication Date
EP0701563A1 EP0701563A1 (fr) 1996-03-20
EP0701563A4 true EP0701563A4 (fr) 1997-07-02

Family

ID=21839568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94910861A Withdrawn EP0701563A4 (fr) 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Country Status (4)

Country Link
EP (1) EP0701563A4 (fr)
JP (1) JPH08511507A (fr)
CA (1) CA2157782A1 (fr)
WO (1) WO1994020517A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
WO1994001139A1 (fr) * 1992-07-13 1994-01-20 Baylor College Of Medicine Ciblage d'une therapie genique somatique en direction des articulations
AU1513495A (en) * 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
JPH10508743A (ja) * 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド インターロイキン−１ タイプ３レセプター
ES2099029B1 (es) * 1994-12-29 1998-01-01 Boeheringer Ingelheim Espana S Empleo del plasmido pmamafgf para preparar farmacos vasorrelajantes y antihipertensivos.
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
CA2273852C (fr) 1996-12-06 2009-09-29 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
JP2001514235A (ja) * 1997-09-02 2001-09-11 カイロン コーポレイション 遺伝子治療を利用して関節炎を処置するための組成物および方法
DK1180159T3 (da) 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3081081B1 (fr) * 2013-12-12 2018-05-23 Mie University Mammifère transgénique non humain exprimant la protéine humaine mmp2
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US12071633B2 (en) 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
WO2023222565A1 (fr) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (fr) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Virus Herpès simplex à titre de vecteur
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique
WO1992011359A1 (fr) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5180182A (en) * 1991-08-26 1993-01-19 Haworth James R Trailer hitch alignment device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (fr) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Virus Herpès simplex à titre de vecteur
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique
WO1992011359A1 (fr) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BANDARA, G. ET AL: "Gene transfer to synoviocytes: prospects for gene treatment of arthritis", DNA CELL BIOL. (1992), 11(3), 227-31 CODEN: DCEBE8;ISSN: 1044-5498, 1992, XP000671125 *
BANDARA, G. ET AL: "Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer", PROC. NATL. ACAD. SCI. U. S. A. (1993), 90(22), 10764-8 CODEN: PNASA6;ISSN: 0027-8424, 1993, XP002029933 *
BLAKE J. ROESSLER ET AL.: "Adenoviral-mediated gene transfer to rabbit synovium in vivo", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 2, August 1993 (1993-08-01), pages 1085 - 1092, XP000671409 *
EVANS C H ET AL.: "Gene transfer to joints for arthritis therapy", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 16, no. F, April 1992 (1992-04-01), pages 46, XP000566580 *
EVANS C H ET AL: "SYNOVIAL CELL TRANSPLANTS FOR GENE TRANSFER TO JOINTS.", FIRST INTERNATIONAL CONGRESS OF THE CELL TRANSPLANT SOCIETY, PITTSBURGH, PENNSYLVANIA, USA, MAY 31-JUNE 3, 1992. TRANSPLANT PROC 24 (6). 1992. 2966. CODEN: TRPPA8 ISSN: 0041-1345, XP000577114 *
G. BANDARA ET AL.: "Intraarticular expression of IRAP by gene transfer", ARTHRITIS AND RHEUMATISM, vol. 35, no. 9, September 1992 (1992-09-01), pages S193, XP000563856 *
HUNG, G.L. ET AL: "Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium", GENE THER. (1994), 1(1), 64-9 CODEN: GETHEC, 1994, XP000671119 *
PAUL D. ROBBINS ET AL.: "Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis", ANNAL NEW YORK ACADEMY OF SCIENCES, vol. 716, June 1993 (1993-06-01), pages 26 - 29, XP000565748 *
See also references of WO9420517A1 *
XIANG GAO ET AL.: "A novel cationic liposome reagent for efficient transfection of mammalian cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 179, no. 1, 30 August 1991 (1991-08-30), ORLANDO, FL US, pages 280 - 285, XP000572654 *

Also Published As

Publication number Publication date
EP0701563A1 (fr) 1996-03-20
JPH08511507A (ja) 1996-12-03
WO1994020517A1 (fr) 1994-09-15
CA2157782A1 (fr) 1994-09-15

Similar Documents

Publication Publication Date Title
EP0701563A4 (fr) Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote
WO2002032962A3 (fr) Procedes et compositions des proteines humaines 80090, 52874, 52880, 63497, et 33425 et leurs utilisations
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
EP2258722A3 (fr) Anticorps anti-polypeptides de type facteur de croissance des fibroblastes
EP1798239A3 (fr) Récepteurs de protéine G-couplés et utilisations correspondantes
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
WO1999033982A3 (fr) Genes humains et produits d'expression genique i
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
WO2000027994A3 (fr) Sequence genomique de chlamydia pneumoniae
WO2001062794A3 (fr) Nouveaux canaux calciques humains 18607
EP1439230A3 (fr) Gène de la protéine transmembranaire humaine TMP-2
AU2001278797A1 (en) Expression vector using for animal cell
EP1053245A4 (fr) 45 proteines humaines secretees
IL122206A0 (en) Adeno-associated virus vectors for gene expression
WO1997003192A3 (fr) Gene du chromosome 1 et produits genetiques lies a la maladie d'alzheimer
WO2000017222A8 (fr) 31 proteines humaines secretees
WO1998011221A3 (fr) Car, un nouveau recepteur du virus de coxsackie et d'adenovirus
EP0744408A3 (fr) Protéine d'ob et son ADN
WO2000077239A3 (fr) Nouveaux genes codant pour des proteines a des fins de diagnostic, de prevention, de therapie et autres
CA2336261A1 (fr) Genes et proteines cycline e2
WO2000008157A3 (fr) Genes humains transporteurs d'anions atnov
WO2000061774A3 (fr) Proteines morphogeniques osseuses bmp
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
GB9622174D0 (en) Gene expression
AU7610396A (en) Connective tissue growth factor-3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROBBINS, PAUL, D.

Inventor name: EVANS, CHRISTOPHER, H.

Inventor name: GLORIOSO, JOSEPH, C.

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched

Effective date: 19970521

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010509

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030319